
Teva gains tentative approval to sell generic Lipitor in 2012
pharmafile | December 5, 2011 | News story | Sales and Marketing | Lipitor, Pfizer, Ranbaxy, Teva
Teva has gained a tentative approval by the FDA to sell its generic form of Pfizer’s blockbuster statin Lipitor next year.
Currently only the Indian firm Ranbaxy is allowed to sell its form of Lipitor (atorvastatin) as it gained first-to-file exclusivity rights.
Under US law this means that Ranbaxy will be the only firm allowed to sell its own form of the drug for the next six months.
After this period, any other firm can enter the market, and the FDA’s approval means Teva is on track to sell its version from May next year.
Teva already has a deal in place with Ranbaxy to help it sell its drug, although terms of the deal were not disclosed.
Watson Pharmaceuticals also has a deal in place with Pfizer to sell Lipitor as a generic, although Pfizer will take around 70% of the drug’s revenue according to reports.
Ben Adams
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …






